Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
Gholam D, Giacchetti S, Brézault-Bonnet C, Bouchahda M, Hauteville D, Adam R, Ducot B, Ghémard O, Kustlinger F, Jasmin C, Lévi F. Gholam D, et al. Among authors: bouchahda m. Oncologist. 2006 Nov-Dec;11(10):1072-80. doi: 10.1634/theoncologist.11-10-1072. Oncologist. 2006. PMID: 17110626 Free article. Clinical Trial.
Cetuximab efficacy in patients treated routinely in university hospitals.
Bachet JB, Afchain P, Fermanian C, Bouchahda M, Mitry E, Landi B, André T, Lièvre A, Louvet C, Aegerter P, Levi F, Rougier P. Bachet JB, et al. Among authors: bouchahda m. Gastroenterol Clin Biol. 2007 Nov;31(11):941-9. doi: 10.1016/s0399-8320(07)78302-1. Gastroenterol Clin Biol. 2007. PMID: 18166882 Free article.
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F, Karaboué A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda M. Lévi F, et al. Among authors: bouchahda m. Cancer Chemother Pharmacol. 2011 Feb;67(2):339-48. doi: 10.1007/s00280-010-1327-8. Epub 2010 Apr 17. Cancer Chemother Pharmacol. 2011. PMID: 20401611 Clinical Trial.
Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
Bouchahda M, Boige V, Smith D, Karaboué A, Ducreux M, Hebbar M, Lepère C, Focan C, Guimbaud R, Innominato P, Awad S, Carvalho C, Tumolo S, Truant S, De Baere T, Castaing D, Rougier P, Morère JF, Taieb J, Adam R, Lévi F; ARTBC International. Bouchahda M, et al. Eur J Cancer. 2016 Nov;68:163-172. doi: 10.1016/j.ejca.2016.09.011. Epub 2016 Oct 18. Eur J Cancer. 2016. PMID: 27768923
Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project.
Innominato PF, Komarzynski S, Mohammad-Djafari A, Arbaud A, Ulusakarya A, Bouchahda M, Haydar M, Bossevot-Desmaris R, Plessis V, Mocquery M, Bouchoucha D, Afshar M, Beau J, Karaboué A, Morère JF, Fursse J, Rovira Simon J, Levi F. Innominato PF, et al. Among authors: bouchahda m. J Med Internet Res. 2016 Nov 25;18(11):e305. doi: 10.2196/jmir.6303. J Med Internet Res. 2016. PMID: 27888171 Free PMC article.
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Lévi F, Karaboué A, Saffroy R, Desterke C, Boige V, Smith D, Hebbar M, Innominato P, Taieb J, Carvalho C, Guimbaud R, Focan C, Bouchahda M, Adam R, Ducreux M, Milano G, Lemoine A. Lévi F, et al. Among authors: bouchahda m. Br J Cancer. 2017 Sep 26;117(7):965-973. doi: 10.1038/bjc.2017.278. Epub 2017 Aug 17. Br J Cancer. 2017. PMID: 28817838 Free PMC article. Clinical Trial.
30 results